
Centre caps trade margin on non-scheduled cancer drugs at 30%
The story in brief
The Centre approved a 30% trade margin cap on non-scheduled cancer drugs, aiming to cut prices of 110 anti-cancer drugs. Patients in Hyderabad and other regions may see reduced treatment costs as high-cost therapies like monoclonal antibodies face price reductions. An expert committee will finalise the list of covered medicines.